AU2015306643B2 - Soluble epoxide hydrolase inhibitors and uses thereof - Google Patents

Soluble epoxide hydrolase inhibitors and uses thereof Download PDF

Info

Publication number
AU2015306643B2
AU2015306643B2 AU2015306643A AU2015306643A AU2015306643B2 AU 2015306643 B2 AU2015306643 B2 AU 2015306643B2 AU 2015306643 A AU2015306643 A AU 2015306643A AU 2015306643 A AU2015306643 A AU 2015306643A AU 2015306643 B2 AU2015306643 B2 AU 2015306643B2
Authority
AU
Australia
Prior art keywords
compound
alkyl
compounds
subject
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015306643A
Other languages
English (en)
Other versions
AU2015306643A1 (en
Inventor
Christoph Dumelin
Anthony D. Keefe
Ying Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
X Chem Inc
Original Assignee
X Chem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X Chem Inc filed Critical X Chem Inc
Publication of AU2015306643A1 publication Critical patent/AU2015306643A1/en
Application granted granted Critical
Publication of AU2015306643B2 publication Critical patent/AU2015306643B2/en
Priority to AU2020207828A priority Critical patent/AU2020207828A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2015306643A 2014-08-28 2015-08-26 Soluble epoxide hydrolase inhibitors and uses thereof Ceased AU2015306643B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020207828A AU2020207828A1 (en) 2014-08-28 2020-07-22 Soluble epoxide hydrolase inhibitors and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043275P 2014-08-28 2014-08-28
US62/043,275 2014-08-28
PCT/US2015/046878 WO2016033150A1 (en) 2014-08-28 2015-08-26 Soluble epoxide hydrolase inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020207828A Division AU2020207828A1 (en) 2014-08-28 2020-07-22 Soluble epoxide hydrolase inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
AU2015306643A1 AU2015306643A1 (en) 2017-03-16
AU2015306643B2 true AU2015306643B2 (en) 2020-05-07

Family

ID=55400481

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015306643A Ceased AU2015306643B2 (en) 2014-08-28 2015-08-26 Soluble epoxide hydrolase inhibitors and uses thereof
AU2020207828A Abandoned AU2020207828A1 (en) 2014-08-28 2020-07-22 Soluble epoxide hydrolase inhibitors and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020207828A Abandoned AU2020207828A1 (en) 2014-08-28 2020-07-22 Soluble epoxide hydrolase inhibitors and uses thereof

Country Status (8)

Country Link
US (2) US10081616B2 (OSRAM)
EP (1) EP3186228A4 (OSRAM)
JP (1) JP2017525777A (OSRAM)
CN (2) CN111454246A (OSRAM)
AU (2) AU2015306643B2 (OSRAM)
CA (1) CA2958881A1 (OSRAM)
MA (1) MA40538A (OSRAM)
WO (1) WO2016033150A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40538A (fr) * 2014-08-28 2021-04-07 X Chem Inc Inhibiteurs de l'époxyde hydrolase soluble et utilisations de ceux-ci
EP3600266B1 (en) * 2017-03-30 2022-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for use in the treatment of cardiovascular calcification
US20230071934A1 (en) * 2019-12-18 2023-03-09 Intra-Cellular Therapies, Inc. Novel uses
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3245950A1 (de) * 1981-12-24 1983-07-07 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur herstellung substituierter pyridine
US20030055088A1 (en) * 2001-09-07 2003-03-20 Euro-Celtique S.A. Aryl substituted pyridines and the use thereof
WO2007098352A2 (en) * 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
WO2008152099A2 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Aryl/hetarylamides as modulators of the ep2 receptor
US20100113512A1 (en) * 2008-10-30 2010-05-06 Diane Michele Ignar Method of treatment using novel antagonists or inverse agonists at opioid receptors
WO2011091410A1 (en) * 2010-01-25 2011-07-28 Glaxos Smithkline Llc Trpv4 antagonists
WO2013057251A2 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ag Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2014075754A1 (en) * 2012-11-16 2014-05-22 Merck Patent Gmbh 3-aminocyclopentane carboxamide derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
WO2007106705A1 (en) * 2006-03-10 2007-09-20 Boehringer Ingelheim International Gmbh Soluble epoxide hydrolase inhibitors and methods of using same
CN101522614B (zh) * 2006-08-09 2014-06-25 史密丝克莱恩比彻姆公司 作为阿片样物质受体的拮抗剂或反向激动剂的化合物
JP2010513458A (ja) * 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
US20110039860A1 (en) * 2008-05-07 2011-02-17 Cangming Yang Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
WO2009153720A1 (en) * 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
US20110306597A1 (en) * 2008-06-18 2011-12-15 James Michael Crawforth Nicotinamide Derivatives
EP2149551A1 (de) * 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) * 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
WO2010080183A1 (en) 2009-01-08 2010-07-15 The Trustees Of Columbia University In The City Of New York Potent non-urea inhibitors of soluble epoxide hydrolase
US20130102601A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
US8809552B2 (en) * 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
CN104136028A (zh) * 2012-01-25 2014-11-05 纽约市哥伦比亚大学理事会 高效可溶性环氧化物水解酶非脲抑制剂
CN104016914B (zh) * 2014-05-27 2016-03-30 苏州科技学院 一种酰胺化合物的制备方法
MA40538A (fr) * 2014-08-28 2021-04-07 X Chem Inc Inhibiteurs de l'époxyde hydrolase soluble et utilisations de ceux-ci

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3245950A1 (de) * 1981-12-24 1983-07-07 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur herstellung substituierter pyridine
US20030055088A1 (en) * 2001-09-07 2003-03-20 Euro-Celtique S.A. Aryl substituted pyridines and the use thereof
WO2007098352A2 (en) * 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
WO2008152099A2 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Aryl/hetarylamides as modulators of the ep2 receptor
US20100113512A1 (en) * 2008-10-30 2010-05-06 Diane Michele Ignar Method of treatment using novel antagonists or inverse agonists at opioid receptors
WO2011091410A1 (en) * 2010-01-25 2011-07-28 Glaxos Smithkline Llc Trpv4 antagonists
WO2013057251A2 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ag Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2014075754A1 (en) * 2012-11-16 2014-05-22 Merck Patent Gmbh 3-aminocyclopentane carboxamide derivatives

Also Published As

Publication number Publication date
EP3186228A1 (en) 2017-07-05
CN111454246A (zh) 2020-07-28
US20180362499A1 (en) 2018-12-20
MA40538A (fr) 2021-04-07
WO2016033150A1 (en) 2016-03-03
CN107074771B (zh) 2020-03-20
CA2958881A1 (en) 2016-03-03
US20170240526A1 (en) 2017-08-24
CN107074771A (zh) 2017-08-18
JP2017525777A (ja) 2017-09-07
EP3186228A4 (en) 2018-04-18
AU2020207828A1 (en) 2020-08-13
US10081616B2 (en) 2018-09-25
AU2015306643A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
US20240294489A1 (en) Low molecular weight protein degraders and their applications
AU2020207828A1 (en) Soluble epoxide hydrolase inhibitors and uses thereof
EP3677584A1 (en) Compound having bruton's tyrosine kinase (btk)-inhibition and degradation activity
EP3703680B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
US10487087B2 (en) Positive allosteric modulators of the GLP-1 receptor
EP3746421B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
WO2013138753A1 (en) Prodrugs of riluzole and their method of use
US12084451B2 (en) Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
EP3697781B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
EP3946390A1 (en) Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
US20200369666A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
AU2018201295A1 (en) Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof
JPWO2016039398A1 (ja) 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物
CA3021558A1 (en) Covalent btk inhibitors and uses thereof
KR20250009417A (ko) 혈액-뇌 장벽 교차 mll1-wdr5 단백질-단백질 상호작용 저해제 화합물 및 이의 용도
CN117466863B (zh) 含芳香族取代基的苯并咪唑化合物及其制备方法和用途
JP2024500919A (ja) 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤
CN118251379B (zh) 铁死亡抑制剂及其用途
JP2025526368A (ja) Ｉｒａｋ３のリガンド指向性分解分子としての置換ピラゾリル－ピリジニル化合物
CN121399101A (zh) Trek(twik相关k+通道)通道功能的抑制剂
CN121443598A (zh) 蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途
KR20150051016A (ko) 구아니딘 화합물 및 이의 용도

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired